William Blair Research Analysts Raise Earnings Estimates for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at William Blair lifted their Q1 2024 earnings estimates for Tarsus Pharmaceuticals in a research report issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the company will post earnings of ($1.16) per share for the quarter, up from their prior estimate of ($1.36). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($4.55) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ FY2024 earnings at ($3.97) EPS and FY2025 earnings at ($1.85) EPS.

A number of other equities analysts have also recently issued reports on TARS. HC Wainwright increased their price objective on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Lifesci Capital reaffirmed an “outperform” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, December 26th. Oppenheimer reiterated an “outperform” rating and issued a $59.00 price target (up from $55.00) on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 28th. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Barclays increased their price target on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $48.38.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS opened at $32.44 on Friday. The stock has a market cap of $1.11 billion, a P/E ratio of -6.99 and a beta of 1.05. Tarsus Pharmaceuticals has a one year low of $12.57 and a one year high of $40.40. The company has a fifty day moving average price of $33.83 and a 200 day moving average price of $24.33. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.93 and a quick ratio of 6.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same quarter in the previous year, the firm posted ($0.49) earnings per share.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in TARS. Royal Bank of Canada boosted its position in Tarsus Pharmaceuticals by 122.0% during the second quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock worth $50,000 after purchasing an additional 1,548 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Tarsus Pharmaceuticals by 310.1% during the third quarter. Tower Research Capital LLC TRC now owns 3,736 shares of the company’s stock worth $66,000 after purchasing an additional 2,825 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Tarsus Pharmaceuticals by 362.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock worth $78,000 after purchasing an additional 3,004 shares during the last quarter. UBS Group AG grew its holdings in shares of Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after purchasing an additional 1,142 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Tarsus Pharmaceuticals by 22.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock valued at $92,000 after acquiring an additional 824 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, insider Aziz Mottiwala sold 4,766 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $145,839.60. Following the sale, the insider now directly owns 54,075 shares in the company, valued at approximately $1,654,695. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Bobak R. Azamian sold 10,415 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $318,699.00. Following the completion of the transaction, the chief executive officer now directly owns 26,456 shares of the company’s stock, valued at $809,553.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Aziz Mottiwala sold 4,766 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $145,839.60. Following the completion of the transaction, the insider now directly owns 54,075 shares of the company’s stock, valued at $1,654,695. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,496 shares of company stock worth $749,578. Company insiders own 11.54% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.